Enrolling more participants from groups underrepresented in biomedical research is a laudable goal, but the current administration's policies may make it hard to achieve.
At a two-day NIH workshop, stakeholders discussed best practices and the challenges of returning results to so many participants with diverse expectations.
The law contains provisions that proponents say will advance precision medicine and speed new tests to market, but critics worry if this will come at a cost to public health.
The DiscovEHR study, conducted by the Regeneron Genetics Center and the Geisinger Health System, uncovered many associations between genetic variants and clinical phenotypes.
NIH has been conservative on the PMI's budget and its funds are sufficient to launch enrollment next year, begin collecting data, and initiate genetic testing pilot projects.
Personalized medicine proponents are uncertain where funding, personnel, and priorities will land in a new administration and Congress.
A beta-testing community is providing feedback on the PMI's recruitment efforts, which are slated to kick off in the first quarter of 2017.
The healthcare provider organizations are tasked with managing patient enrollment in the Precision Medicine Initiative.
Researchers reported on the impact sequencing projects have already had on participants, as well as the challenges, particularly in data interpretation and storage.
The company has been working with the VA since 2013, when it it received a contract to provide sequencing and data analysis for enrollees in the Million Veteran Program.
The Guardian reports that visa costs could prevent scientists and others from coming to the UK.
The Trump Administration is reconsidering its plan to issue an executive order to require federally funded research to be freely available upon publication, Times Higher Education reports.
Nature News says some preprint repositories may close down due to a lack of funds to cover costs.
In Nature this week: framework for analyzing cancer mutational signatures, treatment resistance in small cell lung cancer followed by increased intratumoral heterogeneity, and more.